Peripheral Blood Biomarkers Associated With Outcome in Non-small Cell Lung Cancer Patients Treated With Nivolumab and Durvalumab Monotherapy

Background: Selecting patients who potentially benefit from immune checkpoint inhibitors (ICIs) is critical. Programmed death ligand-1 (PD-L1) protein immunohistochemical expression on cancer cells or immune cells and next-generation sequencing-based tumor mutational burden (TMB) are hot spots in st...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Meilin, Peng, Wenying, Pu, Xingxiang, Chen, Bolin, Li, Jia, Xu, Fang, Liu, Liyu, Xu, Li, Xu, Yan, Cao, Jun, Wang, Qianzhi, Li, Kang, Wang, Jingyi, Wu, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339928/
https://www.ncbi.nlm.nih.gov/pubmed/32695663
http://dx.doi.org/10.3389/fonc.2020.00913

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339928/
https://www.ncbi.nlm.nih.gov/pubmed/32695663
http://dx.doi.org/10.3389/fonc.2020.00913

Ejemplares similares